SCHEMBL12892430

SCHEMBL12892430

CC1(C)OC2C(O1)[C@@H](CO)O[C@H]2n1cnc(C(N)=O)n1

nearest known ligand 0.63

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ LMNA P02545 5/20 0.63
▸ ALDH1A1 P00352 4/20 0.63
▸ SMN1; SMN2 Q16637 3/20 0.63
▸ ADORA1 P30542 2/20 0.63
▸ TSHR P16473 2/20 0.63
▸ THPO P40225 2/20 0.63
▸ PMP22 Q01453 2/20 0.63
▸ GLA P06280 1/20 0.63
▸ EIF4E P06730 1/20 0.63
▸ CYP3A4 P08684 1/20 0.63
▸ TOP1 P11387 1/20 0.63
▸ PI4KA P42356 1/20 0.49
▸ PI4K2B Q8TCG2 1/20 0.49
▸ PI4K2A Q9BTU6 1/20 0.49
▸ PI4KB Q9UBF8 1/20 0.49
▸ PNP P00491 3/20 0.48
▸ TDP1 Q9NUW8 2/20 0.45
▸ HTR2C P28335 1/20 0.41
▸ HTR2B P41595 1/20 0.41
▸ SLC6A3 Q01959 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7377274 1.00 LMNA (0.63) LMNAALDH1A1SMN1; SMN2ADORA1TSHR
SCHEMBL12879149 1.00 LMNA (0.63) LMNAALDH1A1SMN1; SMN2ADORA1TSHR
SCHEMBL3762066 1.00 LMNA (0.63) LMNAALDH1A1SMN1; SMN2ADORA1TSHR
SCHEMBL6839692 1.00 LMNA (0.63) LMNAALDH1A1SMN1; SMN2ADORA1TSHR
SCHEMBL13058163 1.00 LMNA (0.63) LMNAALDH1A1SMN1; SMN2ADORA1TSHR
SCHEMBL24024691 1.00 LMNA (0.63) LMNAALDH1A1SMN1; SMN2ADORA1TSHR
SCHEMBL12879146 0.91 LMNA (0.54) LMNAALDH1A1SMN1; SMN2ADORA1TSHR
SCHEMBL24024511 0.91 LMNA (0.54) LMNAALDH1A1SMN1; SMN2ADORA1TSHR
SCHEMBL13606971 0.88 PNP (0.63) LMNAALDH1A1SMN1; SMN2ADORA1TSHR
SCHEMBL6554011 0.86 LMNA (0.46) LMNAALDH1A1SMN1; SMN2ADORA1TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110039797-A1 Oligomer Conjugates of Heteropentacyclic Nucleosides Nektar Therapetics (US) 2011-02-17 — — US disclosed
WO-2009105258-A1 OLIGOMER CONJUGATES OF HETEROPENTACYCLIC NUCLEOSIDES NEKTAR THERAPEUTICS AL, CORPORATION (US) 2009-08-27 — — WO disclosed
WO-2009085267-A1 ANTIVIRAL COMPOUNDS EPIPHANY BIOSCIENCES (US) 2009-07-09 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110039797-A1 Oligomer Conjugates of Heteropentacyclic Nucleosides SLC29A2, SLC29A1, GNE LMNA 3873/4885ALDH1A1 2313/4885SMN1; SMN2 2799/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback